Olumacostat glasaretil

Drug Profile

Olumacostat glasaretil

Alternative Names: DRM 01; DRM-01B; VAL-001

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator QLT
  • Developer Dermira
  • Class Antiacnes; Furans; Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris

Most Recent Events

  • 03 Mar 2017 Efficacy data from a phase IIb trial in Acne vulgaris presented at 75th Annual Meeting of the American Academy of Dermatology (AAD)
  • 07 Feb 2017 Chemical structure information added
  • 03 Jan 2017 Phase-III clinical trials in Acne vulgaris (In Children, in adolescents, in adults, in elderly) in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top